Clinical Practice Guidelines for the management of locally advanced ...

More documents

Recommendations

Info

and surgery 32–34 survival 18 toxicity 18–21 defined 1 docetaxel 115 emerging therapies 115 node-positive disease external beam radiotherapy 37–38 radiotherapy and androgen deprivation therapy (ADT) 36–37 pathologic T3/T4 disease post radical surgery 34–36 radiotherapy 115 evidence summaries 26, 27, 29, 31, 36 external beam radiotherapy 24–27 pathologic T3/T4 disease post radical surgery 34–36 recommendations 26, 27, 28, 30, 31, 36 surgery 31–32, 115 and androgen deprivation therapy (ADT) 32–34 evidence summaries 32, 34 and radiotherapy 34–36 recommendations 32, 34 survival 18 zoledronic acid 115 locally recurrent 135 loco-regionally progressive disease, and radiotherapy 61–62 luteinising hormone releasing hormone (LHRH) 138 agonist therapy 16, 18–20, 50–52 and bone health 22–23 continuing after hormone refractory 78 metastatic disease 54, 55, 58 side effects 18–19, 53–56 antagonists 54 lycopene 106, 115 lymph 139 lymph glands 139 lymph nodes 16, 36–38, 139 regional 129 magnetic resonance imaging (MRI) 53, 139 Maintaining your well-being: information on depression and anxiety for men with prostate cancer and their partners 12 malignant 139 margin-positive 139 maximal androgen blockages see combined androgen blockage (CAB) medical oncologists 139 mental health 10–12 interventions to improve 5–7 see also depression metastatic 139 metastatic disease androgen deprivation therapy (ADT) choice of 50–51 early versus delayed 52–53 evidence summaries 51, 52, 53, 56, 57, 58 intermittent or continuous 58–59 and non-steroidal anti-androgen 51–52 and quality of life (QOL) 56–57 155 Index
ecommendations 51, 52, 53, 56, 57, 59 single agent versus total androgen blockade 51–52 toxicity 53–56 bisphosphonates 66, 115 bone mineral density (BMD) 22 bone pain 80–83 chemotherapy 88–90 classification of 129 distant 130 docetaxel 115 emerging therapies 115–116 radiotherapy 59–66 survival 50–51 zoledronic acid 115 mitroxantrone 88–90 monitoring 136 mortality rates 1 and ethnicity and race 111 and Indigenous people 111 and literacy levels 111 and rural and remote patients 110–111 and socio-economic status 110 MRI see magnetic resonance imaging (MRI) multdisciplinary care see interdisciplinary care multicultural cancer information services 143 National Cancer Institute, Physician Data Query 115 National Health and Medical Research Council (NHMRC) 117 National Institute of Health (NIH), registry 115 National Palliative Care Strategy 96 nerve root compression 62–65 neuropathic pain 99 nilutamide 53–54, 55 node-positive disease radiotherapy and androgen deprivation therapy (ADT) 36–37 external beam radiotherapy 37–38 nodules 139 non-steroidal anti-androgens 51–52, 54, 55, 57 non-steroidal anti-inflammatory drugs (NSAIDs) 99 nurses, support services 6 nursing care, at home 100 nursing homes 97, 99 nutritional interventions 115 oncologicts 136, 137 orchidectomy 16, 32, 50–51, 55, 139 and bone health 22–23 and cardiovascular disease 19 and lycopene 106 metastatic disease 57 side effects 18–21, 53–56 survival 50–51 osteonecrosis of the jaw 83 osteopaenia 22 osteoporosis 21–23, 79 pain relief 98–99 Clinical practice guidelines for the management of locally advanced and metastatic prostate cancer 156
Page 1:
Clinical Practice Guidelines for th
Page 4 and 5:
4 Biochemical relapse .............
Page 6 and 7:
FOREWORD The management of prostate
Page 8 and 9:
SUMMARY OF CLINICAL PRACTICE RECOMM
Page 10 and 11:
SUMMARY OF RECOMMENDATIONS Chapter
Page 12 and 13:
Chapter Recommendations Grade Refs
Page 14 and 15:
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
1 INTRODUCTION 1.1 Natural history
Page 22 and 23:
2 PSYCHOSOCIAL CARE The diagnosis a
Page 24 and 25:
2.2 Effect of psychological and cog
Page 26 and 27:
Evidence summary Level References T
Page 28 and 29:
Recommendation Men with advanced pr
Page 30 and 31:
An Australian cross-sectional study
Page 32 and 33:
10. Dunn J, et al. A review of peer
Page 34 and 35:
41. Sharpley CF, Christie DRH. An a
Page 36 and 37:
different treatments from different
Page 38 and 39:
Evidence summary Level References I
Page 40 and 41:
Evidence summary Level References F
Page 42 and 43:
Despite these reservations and the
Page 44 and 45:
For non-metastatic disease there we
Page 46 and 47:
Evidence summary Level References T
Page 48 and 49:
monotherapy for low-to-intermediate
Page 50 and 51:
Evidence summary Level References M
Page 52 and 53:
for surgery, suggesting that surger
Page 54 and 55:
Microscopic fully resected node pos
Page 56 and 57:
All three trials demonstrated impro
Page 58 and 59:
Evidence summary Level References B
Page 60 and 61:
of an international multicentre ran
Page 62 and 63:
45. Melton LJ, III, Alothman KI, Kh
Page 64 and 65:
76. Little DJ, Kuban DA, Levy LB, Z
Page 66 and 67:
105. Thompson IM, Tangen CM, Parade
Page 68 and 69:
4.2 Androgen deprivation therapy (e
Page 70 and 71:
Evidence summary Level References F
Page 72 and 73:
therapy since such studies would be
Page 74 and 75:
apparent in trials comparing CAB wi
Page 76 and 77:
QLQ instrument published by Cleary
Page 78 and 79:
Note: Larger well-powered studies h
Page 80 and 81:
Eight trials examined acute toxicit
Page 82 and 83:
half of patients experienced pain r
Page 84 and 85:
olus) in addition to radiotherapy a
Page 86 and 87:
References 1. Seidenfeld J, Samson
Page 88 and 89:
Cooperative Group. Scandinavian Jou
Page 90 and 91:
Oncology Group, TROG 96.05). Radiot
Page 92 and 93:
trial. European Journal of Cancer 1
Page 94 and 95:
6 CASTRATION-RESISTANT PROSTATE CAN
Page 96 and 97:
the median overall survival for pat
Page 98 and 99:
There are two points regarding bisp
Page 100 and 101:
with bone pain at study entry. At n
Page 102 and 103:
Recently, there have been reports o
Page 104 and 105:
of these studies 56, 58 and in the
Page 106 and 107:
Side effects (toxicity) As these ra
Page 108 and 109:
hydrocortisone respectively. Tannoc
Page 110 and 111:
5. Manikandan R, Srirangam SJ, Pear
Page 112 and 113:
33. Elomaa I, Kylmala T, Tammela T
Page 114 and 115:
60. Janknegt RA, Abbou CC, Bartolet
Page 116 and 117:
physiotherapists, occupational ther
Page 118 and 119:
7.5 Q2: Symptom control There was e
Page 120 and 121:
Informal or family caregivers deriv
Page 122 and 123:
8. Hughes SL, Weaver FM, Giobbie-Hu
Page 124 and 125: 8 COMPLEMENTARY AND ALTERNATIVE (UN
Page 126 and 127: corresponding benefit in obstructiv
Page 128 and 129: 3. Eisenberg DM, Kessler RC, Van Ro
Page 130 and 131: areas of the state were more likely
Page 132 and 133: 8 Miller DC, Litwin MS, Bergman J,
Page 134 and 135: 10 EMERGING THERAPIES It is impossi
Page 136 and 137: APPENDIX 1 GUIDELINE DEVELOPMENT PR
Page 138 and 139: study type. Studies published befor
Page 140 and 141: Grade of recommendation Description
Page 142 and 143: 2. National Health and Research Cou
Page 144 and 145: Dr Carole Pinnock AM Principal rese
Page 146 and 147: Surgery Professor Villis Marshall A
Page 148 and 149: APPENDIX 3 TNM CLASSIFICATION OF PR
Page 150 and 151: Summary Prostate T1 T2 T3 T4 N1 M1a
Page 152 and 153: APPENDIX 4 ABBREVIATIONS AND GLOSSA
Page 154 and 155: Glossary Actuarial survival A metho
Page 156 and 157: Effectiveness The extent to which a
Page 158 and 159: Lymph nodes Small, generally pea-si
Page 160 and 161: Each stage is divided into subgroup
Page 162 and 163: APPENDIX 6 - ORGANISATIONS WHICH PR
Page 164 and 165: Consultant Urologist, Royal Brisban
Page 166 and 167: No conflict of interest to declare.
Page 168 and 169: Index to Clinical practice guidelin
Page 170 and 171: cardiovascular mortality 19, 54, 55
Page 172 and 173: androgen deprivation therapy (ADT)
Page 176 and 177: and chemotherapy 89-90 see also bon
Page 178 and 179: spinal cord compression 62-63 see a
Page 180 and 181: systemic 141 Tasmania Association f
show all

Clinical Practice Guidelines for the management of locally advanced ...

Create successful ePaper yourself

Delete template?

Save as template?